A Phase 4 interventional study of Praluent (Alirocumab) and Placebo in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 189 sites in 9 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-05-07.
Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 2nd largest by enrollment, is one of 5 that started in 2016, is one of 5 in phase 4, and was the 34th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,176 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one has the largest enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 2 in phase 4, and was the 9th registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Praluent Regimen - Administration through subcutaneous injection
Drug: Praluent (Alirocumab)
Placebo matching Praluent - Administration through subcutaneous injection
Drug: Placebo
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96
CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance.
Time frame: Week 96
Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96
CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Lower change from baseline raw scores reflect better SWM performance (i.e. less impairment).
Time frame: Week 96
Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96
Percent change from baseline in calculated LDL-C at Week 12, 24, 48, 72, and 96 was reported. LDL-C was measured using conventional units milligram per deciliter (mg/dL).
Time frame: Week 12, 24, 48, 72, and 96
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96
Percent change from baseline in Apo B at Week 12, 24, 48, 72, and 96 was reported. Apo B was measured using conventional units mg/dL.
Time frame: Week 12, 24, 48, 72, and 96
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12, 24, 48, 72, and 96
Percent change from baseline in non-HDL-C at Week 12, 24, 48, 72, and 96 was reported. Non-HDL-C was measured using conventional units mg/dL.
Time frame: Week 12, 24, 48, 72, and 96
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12, 24, 48, 72, and 96
Percent change from baseline in calculated Total-C at Week 12, 24, 48, 72, and 96 was reported. Total-C was measured using conventional units mg/dL.
Time frame: Week 12, 24, 48, 72, and 96
Percent Change From Baseline in Lipoprotein a [Lp(a)] at Week 12, 24, 48, 72, and 96
Percent change from baseline in Lp(a) at Week 12, 24, 48, 72, and 96 was reported. Lp(a) was measured using conventional units mg/dL.
Time frame: Week 12, 24, 48, 72, and 96
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24, 48, 72, and 96
Percent change from baseline in HDL-C at Week 12, 24, 48, 72, and 96 was reported. HDL-C was measured using conventional units mg/dL.
Time frame: Week 12, 24, 48, 72, and 96
Percent Change From Baseline in Triglycerides (TG) at Week 12, 24, 48, 72, and 96
Percent change from baseline in TG at Week 12, 24, 48, 72, and 96 was reported. TG was measured using conventional units mg/dL.
Time frame: Week 12, 24, 48, 72, and 96
Percent Change From Baseline in Apolipoprotein (Apo) A-1 at Week 12, 24, 48, 72, and 96
Percent change from baseline in Apo A-1 at Week 12, 24, 48, 72, and 96 was reported. Apo A-1 was measured using conventional units mg/dL.
Time frame: Week 12, 24, 48, 72, and 96
Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 70 mg/dL (1.81 Millimoles Per Liter [mmol/L]) at Week 12, 24, 48, 72, and 96
Percentage of participants who reached LDL-C level \< 70 mg/dL (1.81 mmol/L) at Week 12, 24, 48, 72, and 96 were reported.
Time frame: Week 12, 24, 48, 72, and 96
Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96
Percentage of participants who reached LDL-C level \< 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96 were reported.
Time frame: Week 12, 24, 48, 72, and 96
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An Adverse Event (AE) was any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. TEAE was defined as AEs that developed or worsened/became serious during on-treatment period (time from the first double-blind study treatment injection up to 70 days after the last double-blind study treatment injection). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participant hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
Time frame: Up to Week 96
A total of 2176 participants were randomized across 169 sites in Bulgaria, Chile, Estonia, Japan, Mexico, Russian Federation, South Africa, Ukraine, and the United States
| Milestone | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Started | 1088 | 1088 |
| Randomized and treated | 1085 | 1086 |
| Completed | 890 | 919 |
| Not completed | 198 | 169 |
| Withdrew: Adverse event | 64 | 67 |
| Withdrew: Poor compliance to protocol | 30 | 26 |
| Withdrew: Physician decision | 4 | 4 |
| Withdrew: Study terminated by sponsor | 4 | 3 |
| Withdrew: Subject moved | 10 | 16 |
| Withdrew: Withdrawal by subject | 64 | 33 |
| Withdrew: Related to imp administration | 3 | 6 |
| Withdrew: Non-disclosed | 16 | 12 |
| Withdrew: Discontinued after randomization and prior to any treatment | 3 | 2 |
CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects better performance.
| Z-score | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96 | -0.180 ± 0.027 | -0.200 ± 0.027 |
CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Lower change from baseline raw scores reflect better SWM performance (i.e. less impairment).
| Units on a Scale | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96 | -0.9 ± 4.49 | -1.0 ± 4.31 |
Percent change from baseline in calculated LDL-C at Week 12, 24, 48, 72, and 96 was reported. LDL-C was measured using conventional units milligram per deciliter (mg/dL).
| Percent Change | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Percent change at Week 12 | 0.6 ± 1.0 | -49.6 ± 0.9 |
| Percent change at Week 24 | 3.0 ± 1.0 | -54.2 ± 1.0 |
| Percent change at Week 48 | 2.8 ± 1.1 | -51.4 ± 1.1 |
| Percent change at Week 72 | 2.4 ± 1.2 | -50.4 ± 1.2 |
| Percent change at Week 96 | 4.0 ± 1.3 | -46.2 ± 1.3 |
Percent change from baseline in Apo B at Week 12, 24, 48, 72, and 96 was reported. Apo B was measured using conventional units mg/dL.
| Percent Change | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Percent change at Week 12 | 0.8 ± 0.7 | -36.7 ± 0.7 |
| Percent change at Week 24 | 2.1 ± 0.8 | -40.9 ± 0.8 |
| Percent change at Week 48 | 1.1 ± 0.8 | -39.0 ± 0.8 |
| Percent change at Week 72 | 0.2 ± 0.9 | -39.1 ± 0.8 |
| Percent change at Week 96 | 1.4 ± 0.9 | -36.4 ± 0.9 |
Percent change from baseline in non-HDL-C at Week 12, 24, 48, 72, and 96 was reported. Non-HDL-C was measured using conventional units mg/dL.
| Percent Change | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Percent change at Week 12 | 0.7 ± 0.8 | -40.4 ± 0.8 |
| Percent change at Week 24 | 2.2 ± 0.9 | -44.0 ± 0.9 |
| Percent change at Week 48 | 1.7 ± 0.9 | -41.1 ± 0.9 |
| Percent change at Week 72 | 1.7 ± 1.0 | -40.6 ± 1.0 |
| Percent change at Week 96 | 2.5 ± 1.1 | -37.0 ± 1.1 |
Percent change from baseline in calculated Total-C at Week 12, 24, 48, 72, and 96 was reported. Total-C was measured using conventional units mg/dL.
| Percent Change | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Percent change at Week 12 | -0.3 ± 0.6 | -29.6 ± 0.6 |
| Percent change at Week 24 | 1.5 ± 0.6 | -31.8 ± 0.6 |
| Percent change at Week 48 | 1.1 ± 0.7 | -29.6 ± 0.7 |
| Percent change at Week 72 | 1.1 ± 0.7 | -29.0 ± 0.7 |
| Percent change at Week 96 | 1.8 ± 0.7 | -26.5 ± 0.7 |
Percent change from baseline in Lp(a) at Week 12, 24, 48, 72, and 96 was reported. Lp(a) was measured using conventional units mg/dL.
| Percent Change | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Percent change at Week 12 | -3.3 ± 0.8 | -22.4 ± 0.8 |
| Percent change at Week 24 | -0.5 ± 0.9 | -24.7 ± 0.9 |
| Percent change at Week 48 | -1.4 ± 1.0 | -24.3 ± 1.0 |
| Percent change at Week 72 | -1.7 ± 1.0 | -25.1 ± 1.0 |
| Percent change at Week 96 | 4.8 ± 1.1 | -17.7 ± 1.1 |
Percent change from baseline in HDL-C at Week 12, 24, 48, 72, and 96 was reported. HDL-C was measured using conventional units mg/dL.
| Percent Change | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Percent change at Week 12 | 0.6 ± 0.5 | 5.9 ± 0.5 |
| Percent change at Week 24 | 3.8 ± 0.6 | 9.0 ± 0.6 |
| Percent change at Week 48 | 3.8 ± 0.6 | 9.2 ± 0.6 |
| Percent change at Week 72 | 4.4 ± 0.7 | 10.3 ± 0.6 |
| Percent change at Week 96 | 5.5 ± 0.7 | 10.8 ± 0.7 |
Percent change from baseline in TG at Week 12, 24, 48, 72, and 96 was reported. TG was measured using conventional units mg/dL.
| Percent Change | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Percent change at Week 12 | 0.7 ± 1.0 | -11.0 ± 1.0 |
| Percent change at Week 24 | -1.8 ± 1.0 | -12.9 ± 1.0 |
| Percent change at Week 48 | -1.8 ± 1.1 | -11.3 ± 1.1 |
| Percent change at Week 72 | -2.1 ± 1.1 | -12.3 ± 1.1 |
| Percent change at Week 96 | -2.7 ± 1.1 | -11.9 ± 1.1 |
Percent change from baseline in Apo A-1 at Week 12, 24, 48, 72, and 96 was reported. Apo A-1 was measured using conventional units mg/dL.
| Percent Change | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Percent change at Week 12 | -1.3 ± 0.4 | 1.7 ± 0.4 |
| Percent change at Week 24 | 2.9 ± 0.4 | 6.1 ± 0.4 |
| Percent change at Week 48 | 4.7 ± 0.4 | 7.7 ± 0.4 |
| Percent change at Week 72 | 4.4 ± 0.4 | 7.8 ± 0.4 |
| Percent change at Week 96 | 4.2 ± 0.4 | 7.5 ± 0.4 |
Percentage of participants who reached LDL-C level \< 70 mg/dL (1.81 mmol/L) at Week 12, 24, 48, 72, and 96 were reported.
| Percentage of Participants | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Week 12 | 10.3 | 69.4 |
| Week 24 | 8.4 | 74.7 |
| Week 48 | 10.7 | 71.4 |
| Week 72 | 11.3 | 69.7 |
| Week 96 | 10.7 | 64.5 |
Percentage of participants who reached LDL-C level \< 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96 were reported.
| Percentage of Participants | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Week 12 | 1.7 | 45.6 |
| Week 24 | 2.0 | 56.9 |
| Week 48 | 2.1 | 51.3 |
| Week 72 | 2.5 | 52.1 |
| Week 96 | 2.4 | 46.4 |
An Adverse Event (AE) was any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. TEAE was defined as AEs that developed or worsened/became serious during on-treatment period (time from the first double-blind study treatment injection up to 70 days after the last double-blind study treatment injection). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-participant hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
| Participants | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Participants with any TEAEs | 857 | 866 |
| Participants with any Serious TEAEs | 216 | 189 |
| Participants with any TEAE leading to death | 17 | 13 |
| Participants with any TEAE leading to permanent treatment discontinuation | 59 | 64 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the end of study (Week 96) regardless of seriousness or relationship to investigational product (IP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 24/1,084 (2.2%) | 216/1,084 (19.9%) | 387/1,084 (35.7%) |
| Alirocumab 75 Q2W/Up150 Q2W | 17/1,087 (1.6%) | 189/1,087 (17.4%) | 366/1,087 (33.7%) |
| Event | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| Angina unstableCardiac disorders | 16/1084 | 14/1087 |
| Atrial fibrillationCardiac disorders | 13/1084 | 5/1087 |
| Angina pectorisCardiac disorders | 10/1084 | 11/1087 |
| Coronary artery diseaseCardiac disorders | 8/1084 | 6/1087 |
| Acute myocardial infarctionCardiac disorders | 7/1084 | 5/1087 |
| HypertensionVascular disorders | 7/1084 | 6/1087 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/1084 | 6/1087 |
| PneumoniaInfections and infestations | 5/1084 | 4/1087 |
| Ischaemic strokeNervous system disorders | 5/1084 | 4/1087 |
| Acute coronary syndromeCardiac disorders | 4/1084 | 1/1087 |
| Event | Placebo | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|---|
| NasopharyngitisInfections and infestations | 89/1084 | 82/1087 |
| HeadacheNervous system disorders | 85/1084 | 71/1087 |
| HypertensionVascular disorders | 73/1084 | 64/1087 |
| Back painMusculoskeletal and connective tissue disorders | 71/1084 | 60/1087 |
| InfluenzaInfections and infestations | 69/1084 | 63/1087 |
| BronchitisInfections and infestations | 65/1084 | 60/1087 |
| Urinary tract infectionInfections and infestations | 46/1084 | 61/1087 |
Safety population (SAF) included all participants randomized and exposed to at least one dose of study drug, regardless of the amount of treatment administered.
| Age, Continuous(Years) | Placebo | Alirocumab 75 Q2W/Up150 Q2W | Total |
|---|---|---|---|
| Mean | 62.7 ± 9.02 | 62.6 ± 8.88 | 62.6 ± 8.95 |
| Sex: Female, Male(Participants) | Placebo | Alirocumab 75 Q2W/Up150 Q2W | Total |
|---|---|---|---|
| Female | 459 | 448 | 907 |
| Male | 625 | 639 | 1264 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Alirocumab 75 Q2W/Up150 Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 137 | 142 | 279 |
| Not Hispanic or Latino | 945 | 943 | 1888 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | Placebo | Alirocumab 75 Q2W/Up150 Q2W | Total |
|---|---|---|---|
| White | 888 | 886 | 1774 |
| Black or African American | 86 | 77 | 163 |
| Asian | 19 | 28 | 47 |
| American Indian or Alaska Native | 11 | 16 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 80 | 80 | 160 |
| CANTAB Cognitive Domain Spatial Working Memory (SWM) Strategy Raw Score(Units on a Scale) | Placebo | Alirocumab 75 Q2W/Up150 Q2W | Total |
|---|---|---|---|
| Mean | 15.9 ± 5.03 | 16.05 ± 5.11 | 16.0 ± 5.07 |
Showing the first 100 of 189 sites across 9 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Mar 2020, 40 months.
Results were first posted in May 2021, 1 year 2 months after primary completion.
Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 40 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab